KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Non-Current Liabilities: 2017-2025

Historic Other Non-Current Liabilities for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $2.1 million.

  • Aquestive Therapeutics' Other Non-Current Liabilities rose 1.23% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 1.23%. This contributed to the annual value of $2.4 million for FY2024, which is 18.80% up from last year.
  • Aquestive Therapeutics' Other Non-Current Liabilities amounted to $2.1 million in Q3 2025, which was up 0.29% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Other Non-Current Liabilities registered a high of $2.5 million during Q4 2021, and its lowest value of $1.8 million during Q1 2021.
  • For the 3-year period, Aquestive Therapeutics' Other Non-Current Liabilities averaged around $2.1 million, with its median value being $2.0 million (2024).
  • Within the past 5 years, the most significant YoY rise in Aquestive Therapeutics' Other Non-Current Liabilities was 34.41% (2022), while the steepest drop was 18.15% (2022).
  • Over the past 5 years, Aquestive Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $2.5 million in 2021, then dropped by 18.15% to $2.0 million in 2022, then dropped by 0.88% to $2.0 million in 2023, then increased by 18.80% to $2.4 million in 2024, then increased by 1.23% to $2.1 million in 2025.
  • Its Other Non-Current Liabilities stands at $2.1 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.2 million for Q1 2025.